Press Releases VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-13 pm EDT			5-day change	1st Jan Change
0.5913 ^USD	+0.66%		-0.64%	+1.93%

Feb. 27	VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Dec. 18	RTW Biotech Opportunities announces new investment in Yarrow Bioscience	RE

Press Releases

Dec. 17	VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement	AQ
Nov. 06	VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update	AQ
25-08-14	VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update	AQ
25-08-14	VYNE Therapeutics : Repibresib Phase 2b Vitiligo Topline Results & Additional Analyses	PU
25-07-30	VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo	AQ
25-07-30	VYNE Therapeutics : Repibresib Phase 2b Vitiligo Topline Results	PU
25-07-02	VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202	AQ
25-05-08	VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update	AQ
25-04-25	VYNE Therapeutics Provides Update on VYN202 Program	AQ
25-03-20	VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference	AQ
25-03-06	VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update	AQ
25-02-20	VYNE Therapeutics to Participate in March Investor Conferences	AQ
25-02-19	VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis	AQ
25-01-06	VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo	AQ
24-12-23	VYNE Therapeutics : Reports Positive Top line Phase 1a MAD Data for VYN202, its Novel BD2 Selective BET Inhibitor Form 8 K	PU
24-12-23	VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor	AQ
24-11-07	VYNE Therapeutics : Reports Third Quarter 2024 Financial Results and Provides Business Update Form 8 K	PU
24-11-07	VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update	AQ
24-09-12	VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor	AQ
24-09-03	VYNE Therapeutics to Participate in September Investor Conferences	AQ
24-08-14	VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update	AQ
24-07-16	VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor	AQ
24-07-09	VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development	AQ
24-06-26	VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum	AQ
24-06-13	VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202	AQ